{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:56:59Z","timestamp":1784735819630,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06567-9","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:17:35Z","timestamp":1757582255000},"page":"5027-5035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multicenter, real-world observational study of AVA therapy following ELT\/HET switching in Chinese children with persistent\/chronic primary ITP"],"prefix":"10.1007","volume":"104","author":[{"given":"Jingjing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"6567_CR1","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.blre.2023.101112","volume":"61","author":"TJ Gonzalez-Lopez","year":"2023","unstructured":"Gonzalez-Lopez TJ et al (2023) Primary and secondary immune thrombocytopenia (ITP): time for a rethink. Blood Rev 61:101112","journal-title":"Blood Rev"},{"issue":"6","key":"6567_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","volume":"27","author":"JW Semple","year":"2020","unstructured":"Semple JW et al (2020) An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol 27(6):423\u2013429","journal-title":"Curr Opin Hematol"},{"issue":"4\u20135","key":"6567_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.autrev.2014.01.026","volume":"13","author":"E Lo","year":"2014","unstructured":"Lo E, Deane S (2014) Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 13(4\u20135):577\u2013583","journal-title":"Autoimmun Rev"},{"issue":"23","key":"6567_CR4","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C et al (2019) American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866","journal-title":"Blood Adv"},{"issue":"1","key":"6567_CR5","doi-asserted-by":"publisher","first-page":"e26736","DOI":"10.1002\/pbc.26736","volume":"65","author":"M Carolyn","year":"2018","unstructured":"Carolyn M, Bennett et al (2018) Predictors of remission in children with newly diagnosed immune thrombocytopenia data from the intercontinental cooperative ITP study group registry II participants. Pediatr Blood Cancer 65(1):e26736","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"6567_CR6","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817","journal-title":"Blood Adv"},{"issue":"16","key":"6567_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Avatrombopag (2021) A review in thrombocytopenia. Drugs 81(16):1905\u20131913","journal-title":"Drugs"},{"key":"6567_CR8","doi-asserted-by":"publisher","first-page":"204062072311798","DOI":"10.1177\/20406207231179856","volume":"14","author":"A Oladapo","year":"2023","unstructured":"Oladapo A et al (2023) Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study. Ther Adv Hematol 14:20406207231179856","journal-title":"Ther Adv Hematol"},{"issue":"13","key":"6567_CR9","first-page":"1581","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY (2021) Hetrombopag: first approval. Drugs (New York, NY) 81(13):1581\u20131585","journal-title":"Drugs (New York, NY)"},{"issue":"3","key":"6567_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bjh.18864","volume":"202","author":"X Cheng","year":"2023","unstructured":"Cheng X et al (2023) Outcomes of switching to Avatrombopag following treatment failure with Eltrombopag in paediatric immune thrombocytopenia: A real-world study in China. Br J Haematol 202(3):636\u2013644","journal-title":"Br J Haematol"},{"issue":"16","key":"6567_CR11","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C et al (2011) The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117(16):4190\u20134207","journal-title":"Blood"},{"issue":"10","key":"6567_CR12","first-page":"810","volume":"59","author":"WGOC Thrombocytopenia","year":"2021","unstructured":"Thrombocytopenia WGOC (2021) The subspecialty group of hematologic diseases and C.J.O.P. The editorial board, adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021). Chin J Pediatr 59(10):810\u2013819","journal-title":"Chin J Pediatr"},{"key":"6567_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0"},{"issue":"5","key":"6567_CR14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/bjh.19342","volume":"204","author":"Z Wang","year":"2024","unstructured":"Wang Z et al (2024) Efficacy and safety of Avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol 204(5):1958\u20131965","journal-title":"Br J Haematol"},{"issue":"11","key":"6567_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","volume":"81","author":"J Gilreath","year":"2021","unstructured":"Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 81(11):1285\u20131305","journal-title":"Drugs"},{"issue":"1","key":"6567_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H et al (2021) A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol 14(1):37","journal-title":"J Hematol Oncol"},{"issue":"8","key":"6567_CR17","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315\u2013e325","journal-title":"Lancet Haematol"},{"issue":"10004","key":"6567_CR18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD et al (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649\u20131658","journal-title":"Lancet"},{"issue":"3","key":"6567_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/bjh.19253","volume":"204","author":"Z Wang","year":"2024","unstructured":"Wang Z et al (2024) Long-term Eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. Br J Haematol 204(3):1017\u20131023","journal-title":"Br J Haematol"},{"issue":"6","key":"6567_CR20","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1111\/bjh.19345","volume":"204","author":"N Cooper","year":"2024","unstructured":"Cooper N et al (2024) Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the united kingdom: results from the TRAIT study. Br J Haematol 204(6):2442\u20132452","journal-title":"Br J Haematol"},{"issue":"3","key":"6567_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","volume":"155","author":"N Terrault","year":"2018","unstructured":"Terrault N et al (2018) Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 155(3):705\u2013718","journal-title":"Gastroenterology"},{"issue":"3","key":"6567_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","volume":"197","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H et al (2022) Adults with immune thrombocytopenia who switched to Avatrombopag following prior treatment with Eltrombopag or romiplostim: A multicentre US study. Br J Haematol 197(3):359\u2013366","journal-title":"Br J Haematol"},{"issue":"2","key":"6567_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","volume":"33","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Nagalla S (2022) Efficacy and safety evaluation of Avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets 33(2):257\u2013264","journal-title":"Platelets"},{"issue":"4","key":"6567_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/bjh.18908","volume":"202","author":"MD Tarantino","year":"2023","unstructured":"Tarantino MD et al (2023) A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of Avatrombopag versus Eltrombopag in ITP. Br J Haematol 202(4):897\u2013899","journal-title":"Br J Haematol"},{"issue":"25","key":"6567_CR25","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel JB et al (2014) A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123(25):3887\u20133894","journal-title":"Blood"},{"key":"6567_CR26","unstructured":"Biovitrum SO (2020) DOPTELET\u00ae(avatrombopag): US pre-scribing information. Accessed 17 Sep 2021"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06567-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:02:54Z","timestamp":1763420574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06567-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6567"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06567-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6187960\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}